Cargando…

Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania

BACKGROUND: Hydroxyurea (HU) has been demonstrated to be efficacious in reducing complications in individuals with sickle cell anemia (SCA) but poor adherence is a barrier. Directly Observed Therapy (DOT) has been shown to improve adherence in various chronic diseases but there is limited data in ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makubi, Abel, Sasi, Philip, Ngaeje, Mariam, Novelli, Enrico M., Mmbando, Bruno P., Gladwin, Mark T., Makani, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069827/ https://www.ncbi.nlm.nih.gov/pubmed/27756209 http://dx.doi.org/10.1186/s12874-016-0245-9

Ejemplares similares

Possible Risk Factors for Severe Anemia in Hospitalized Sickle Cell Patients at Muhimbili National Hospital, Tanzania: Protocol for a Cross-Sectional Study
por: Tluway, Furahini, et al.
Publicado: (2018)

Fetal Hemoglobin is Associated with Peripheral Oxygen Saturation in Sickle Cell Disease in Tanzania
por: Nkya, Siana, et al.
Publicado: (2017)

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
por: Di Maggio, Rosario, et al.
Publicado: (2018)

Decreased Hepcidin Levels Are Associated with Low Steady-state Hemoglobin in Children With Sickle Cell Disease in Tanzania
por: Lee, Nathaniel, et al.
Publicado: (2018)

A ten year review of the sickle cell program in Muhimbili National Hospital, Tanzania
por: Makani, Julie, et al.
Publicado: (2018)

Rationale, design and protocol of a cross-sectional study on pregnancy-related cardiovascular diseases in Tanzania (PRECARDT): burden, characterisation and prognostic significance at delivery
por: Makubi, Abel, et al.
Publicado: (2021)

Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost
por: Costa, Enrico, et al.
Publicado: (2020)

Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators
por: Mlyuka, Hamu J., et al.
Publicado: (2022)

Prevalence and Factors Associated with Human Parvovirus B19 Infection in Sickle Cell Patients Hospitalized in Tanzania
por: Urio, Florence, et al.
Publicado: (2019)

Relationships between sickle cell trait, malaria, and educational outcomes in Tanzania
por: Croke, Kevin, et al.
Publicado: (2017)

Genetic variants at HbF‐modifier loci moderate anemia and leukocytosis in sickle cell disease in Tanzania
por: Mtatiro, Siana Nkya, et al.
Publicado: (2014)

Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania
por: Ambrose, Emmanuela E, et al.
Publicado: (2023)

Tanzania's position on the COVID-19 pandemic
por: Mfinanga, Sayoki G, et al.
Publicado: (2021)

Patterns and patient factors associated with loss to follow-up in the Muhimbili sickle cell cohort, Tanzania
por: Masamu, Upendo, et al.
Publicado: (2020)

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine
por: Kilonzi, Manase, et al.
Publicado: (2022)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Mobile direct observation of therapy (MDOT) - A rapid systematic review and pilot study in children with asthma
por: Shields, Michael D., et al.
Publicado: (2018)

Genome Wide Association Study of Fetal Hemoglobin in Sickle Cell Anemia in Tanzania
por: Mtatiro, Siana Nkya, et al.
Publicado: (2014)

Anaemia and iron deficiency in heart failure: epidemiological gaps, diagnostic challenges and therapeutic barriers in sub-Saharan Africa
por: Makubi, Abel, et al.
Publicado: (2017)

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma
por: Ciprotti, Marika, et al.
Publicado: (2014)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Development of multi-level standards of care recommendations for sickle cell disease: Experience from SickleInAfrica
por: Paintsil, Vivian, et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment
por: D’Alessandro, Angelo, et al.
Publicado: (2023)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Genetic association of fetal-hemoglobin levels in individuals with sickle cell disease in Tanzania maps to conserved regulatory elements within the MYB core enhancer
por: Mtatiro, Siana N, et al.
Publicado: (2015)

Infrastructure for bioinformatics applications in Tanzania: Lessons from the Sickle Cell Programme
por: Mwita, Liberata A., et al.
Publicado: (2023)

Xin hua jing /
Publicado: (1982)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lbvkbl6v6hvfv86alber17bj4a